Mode
Text Size
Log in / Sign up

Multimodality cardiac imaging aids differentiation between hypertrophic cardiomyopathy and cardiac amyloidosisImaging helps doctors tell apart two heart conditions causing thickened heart muscle

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider multimodality imaging patterns to help differentiate HCM from CA, but confirm diagnosis clinically.

This narrative review synthesizes evidence on the use of multimodality cardiac imaging—specifically echocardiography and cardiac MRI—to differentiate hypertrophic cardiomyopathy (HCM) from cardiac amyloidosis (CA) in patients presenting with myocardial thickening. The review does not report a specific sample size, study setting, or comparator, and it is based on a synthesis of existing literature rather than new patient data.

The review describes characteristic echocardiographic features for each condition. For HCM, these include asymmetric septal hypertrophy, dynamic left ventricular outflow tract obstruction, and systolic anterior motion of the mitral valve. For CA, features include concentric wall thickening, biatrial enlargement, restrictive filling, and an "apical sparing" strain pattern. On cardiac MRI, HCM is associated with patchy mid-wall or junctional fibrosis on late gadolinium enhancement (LGE), while CA shows diffuse LGE involving the subendocardium or full wall thickness. Mapping parameters show mildly elevated native T1 and extracellular volume (ECV) in HCM versus markedly increased values in CA. No quantitative effect sizes, absolute numbers, or statistical measures are reported for these findings.

Safety and tolerability data for the imaging modalities are not reported. Key limitations include the descriptive nature of the review, the lack of reported quantitative data or comparative performance metrics, and the absence of information on funding or conflicts of interest. The practice relevance is that differentiating HCM from CA is clinically crucial due to differing management strategies and prognoses, but this review provides a qualitative summary of imaging patterns rather than definitive diagnostic criteria.

Doctors reviewed existing research on how to use heart imaging tests to tell apart two different heart conditions. Both hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA) cause the heart muscle to thicken, but they are treated very differently. The review focused on patients already diagnosed with a thickened heart muscle, looking at patterns seen on echocardiograms (heart ultrasounds) and cardiac MRIs.

The review found that these two imaging methods can show different clues for each condition. On ultrasound, HCM often shows uneven thickening and specific movement of a heart valve, while CA tends to show more even thickening and a different pattern of how the heart squeezes. On MRI scans, the pattern of scarring and special measurements of heart tissue also look different between the two diseases.

No new safety information was reported, as this was a review of how doctors already use these standard tests. The main reason to be careful is that the two conditions can look very similar, especially early on, which can make diagnosis tricky. This review helps organize what doctors currently look for, but it does not provide new data on how accurate these methods are in real-world practice.

Readers should understand that this is a summary of expert knowledge, not a breakthrough. It explains the tools cardiologists use to make a precise diagnosis, which is crucial for getting the right treatment. If you have questions about heart imaging, your doctor is the best person to discuss what specific tests mean for you.

What this means for you:
Heart imaging shows different patterns for two thickening heart conditions, helping guide diagnosis.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMar 2026
View Original Abstract ↓
Hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA) are major causes of myocardial thickening, yet they arise from distinct genetic, structural, and pathophysiological mechanisms. Differentiating these entities is clinically crucial, as management strategies and prognostic implications differ substantially. However, overlapping phenotypic features, particularly left ventricular hypertrophy, frequently complicate diagnosis. Recent advances in multimodality cardiac imaging have markedly improved the ability to distinguish HCM from CA through refined anatomical assessment and non-invasive tissue characterization. Echocardiography helps evaluate ventricular structure, diastolic function, and flow patterns. Asymmetric septal hypertrophy, dynamic left ventricular outflow tract (LVOT) obstruction, and systolic anterior motion (SAM) of the mitral valve are characteristic of HCM, while concentric wall thickening, biatrial enlargement, restrictive filling, and the “apical sparing” strain pattern point toward CA. Cardiac MRI adds further diagnostic value through tissue characterization. In HCM, late gadolinium enhancement (LGE) typically appears as patchy mid-wall or junctional fibrosis, whereas in CA it is diffuse, involving the subendocardium or the full wall thickness. Mapping parameters also help differentiate the two conditions: native T1 and ECV are mildly elevated in HCM but markedly increased in CA due to extensive extracellular amyloid deposition.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.